Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Cutaneous T-cell lymphomas (CTCL) are incurable non-Hodgkin lymphomas.
• The efficacy of allogeneic hematopoietic stem cell transplant (HSCT) for CTCL is not well-established.
• Allogeneic HSCT may offer graft-versus-lymphoma (GVL) activity.

Purpose of the Study:

• To evaluate the outcomes of allogeneic HSCT in extensively pretreated CTCL patients.
• To assess the graft-versus-lymphoma (GVL) effect in CTCL patients undergoing HSCT.
• To determine the safety and efficacy of reduced intensity conditioning regimens in this context.

Main Methods:

• Retrospective analysis of 12 extensively pretreated CTCL patients.
• Allogeneic HSCT with a focus on reduced intensity conditioning regimens.
• Assessment of complete remission (CR), treatment-related mortality (TRM), and disease-free survival (DFS).

Main Results:

• Six patients achieved complete remission (CR) with active disease at transplantation, indicating a GVL effect.
• Treatment-related mortality (TRM) was low.
• 42% of patients were alive and disease-free at a median of 22 months post-transplant.
• Two patients demonstrated direct GVL effects upon immunosuppression withdrawal or donor lymphocyte infusion.

Conclusions:

• Allogeneic HSCT can achieve long-term disease control in advanced CTCL.
• HSCT provides a viable treatment option for CTCL refractory to conventional therapies.
• The GVL effect is a significant factor in the success of HSCT for CTCL.